A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT ID: NCT00404612


Title
A Double-Masked, Placebo-Controlled, Parallel Group, Multi-Center, Dose-Ranging Study With an Optional Extension to Assess the Efficacy and Safety of LX211 as Therapy in Subjects With Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
Purpose
The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis
Details
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Keywords
uveitis, calcineurin
Source
Lux Biosciences, Inc.
Sponsors
Lux Biosciences, Inc.
Status
Completed
Acronym
LUMINATE
Last Updated
08 Oct 2012
URL
Official Link
Locations
Austria, Canada, France, Germany, India, United Kingdom, United States